PfSPZ-LARC2 Malaria Vaccine Advances to New Age Groups After Successful Safety Review

PfSPZ-LARC2 malaria vaccine advances to new age groups after successful safety review

Physician-scientists at Groupe de Recherche Action en Santé (GRAS) in Burkina Faso have successfully completed initial safety evaluations in 30 adult Burkinabés as the first phase of a clinical trial of Sanaria PfSPZ-LARC2 Vaccine, which is designed to prevent infection with Plasmodium falciparum malaria.

Advances in molecular genetic systems in malaria

Crabb and colleagues discuss the molecular genetics systems that are currently available forPlasmodium falciparum and Plasmodium berghei, including conditional systems and gene editing tools, and examine the insights that have been gained into the function of genes that are important during the blood stages of the parasites. Robust tools for analysing gene function in Plasmodium parasites, which are the causative agents of malaria, are being dev…

Africa: Will Funding Match Demand? Africa's Malaria Vaccine Program Faces Crunch

"The global malaria vaccination program is at a critical juncture... proof of high demand, but without urgent funding, this progress could unravel."

Malaria Vaccination Program at Critical Juncture Due to Funding Shortfall – Media Talk Africa

Malaria Vaccine Rollout at Critical Juncture: Funding Shortfall Threatens Progress The global malaria vaccination program is facing a critical moment, […] Source